array(3) { ["company_details"]=> array(13) { ["name"]=> string(26) "Bio-RAD Laboratories, Inc." ["slug"]=> string(33) "001cd-us-bio-rad-laboratories-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920" ["description"]=> string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together. #Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics" ["address_street"]=> string(20) "1000 Alfred Nobel Dr" ["address_place"]=> string(8) "Hercules" ["address_region"]=> string(10) "California" ["founding_date"]=> string(10) "1952-02-08" ["website_domain"]=> string(11) "bio-rad.com" ["website_url"]=> string(23) "https://www.bio-rad.com" ["industry_codes"]=> array(3) { [0]=> string(42) "In Vitro and In Vivo Diagnostic Substances" [1]=> string(33) "Laboratory Analytical Instruments" [2]=> string(47) "Electromedical and Electrotherapeutic Apparatus" } ["employee_count"]=> int(7900) ["article_count"]=> int(659) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(56) "OncoCyte reports Q4 revenue $314,000, consensus $320,000" ["snippet_en"]=> string(169) "Loss from operations for the three months ended December 31, 2023, was $16.2M, an increase of 39% compared to fourth quarter 2022. “In 2023, we made significant pro..." ["url"]=> string(89) "https://www.tipranks.com/news/the-fly/oncocyte-reports-q4-revenue-314000-consensus-320000" ["image_url"]=> NULL ["source"]=> string(12) "tipranks.com" ["publication_date"]=> string(10) "2024-04-12" ["categories"]=> array(1) { [0]=> string(24) "Quarterly/Annual Figures" } } [1]=> array(7) { ["title_en"]=> string(29) "Bio-Rad: Q4 Earnings Snapshot" ["snippet_en"]=> string(149) "HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO) on Thursday reported fourth-quarter net income of $349.7 million." ["url"]=> string(54) "https://qz.com/bio-rad-q4-earnings-snapshot-1851262346" ["image_url"]=> string(78) "https://images.businessradar.com/articles/9b293a3b-2ac2-4e87-a921-554e4e3a42ad" ["source"]=> string(6) "qz.com" ["publication_date"]=> string(10) "2024-02-15" ["categories"]=> array(1) { [0]=> string(24) "Quarterly/Annual Figures" } } [2]=> array(7) { ["title_en"]=> string(84) "Zacks Research Weighs in on Bio-Rad Laboratories, Inc.'s Q1 2025 Earnings (NYSE:BIO)" ["snippet_en"]=> string(300) "Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Stock analysts at Zacks Research cut their Q1 2025 EPS estimates for Bio-Rad Laboratories in a research note issued to investors on Tuesday, January 16th. Zacks Research analyst R. Anand now forecasts that the medical research company will pos" ["url"]=> string(89) "https://www.marketbeat.com/instant-alerts/nyse-bio-analyst-earnings-estimates-2024-01-19/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/4c2cc902-3ad5-47d1-82b6-b5f42dbe6540" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-01-19" ["categories"]=> array(7) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(9) "Investors" [2]=> string(24) "Stock Research & Ratings" [3]=> string(13) "Credit Rating" [4]=> string(17) "Academic Research" [5]=> string(12) "Stock Market" [6]=> string(5) "R & D" } } [3]=> array(7) { ["title_en"]=> string(66) "Hologic (HOLX) Q4 Earnings Might Rise on 7.7% Breast Health Growth" ["snippet_en"]=> string(124) "Strength in Breast Health and growing Panther instrument installed base will likely benefit Hologic's (HOLX) Q4 performance." ["url"]=> string(76) "https://finance.yahoo.com/news/hologic-holx-q4-earnings-might-140300066.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a5950dd7-62fa-44d5-ba53-b407218b5081" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-10-30" ["categories"]=> array(3) { [0]=> string(29) "Delivery Delays/ Cancellation" [1]=> string(24) "Quarterly/Annual Figures" [2]=> string(21) "Financial Performance" } } [4]=> array(7) { ["title_en"]=> string(70) "Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Earnings Call Transcript" ["snippet_en"]=> string(274) "Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Earnings Call Transcript October 26, 2023 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.33 EPS, expectations were $2.87. Operator: Good afternoon, ladies and gentlemen. Thank you for standing by." ["url"]=> string(75) "https://finance.yahoo.com/news/bio-rad-laboratories-inc-nyse-152149401.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/2d4eeda8-5b9c-4d2d-8687-c32614acbcd3" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-10-27" ["categories"]=> array(1) { [0]=> string(24) "Quarterly/Annual Figures" } } [5]=> array(7) { ["title_en"]=> string(66) "Bio-Rad Laboratories (BIO) Q3 Earnings and Revenues Miss Estimates" ["snippet_en"]=> string(188) "Bio-Rad (BIO) delivered earnings and revenue surprises of -18.82% and 8.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?" ["url"]=> string(73) "https://finance.yahoo.com/news/bio-rad-laboratories-bio-q3-214015742.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/54218d72-8d2f-496a-b2cb-e093122752ad" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-10-26" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(12) "Stock Market" } } [6]=> array(7) { ["title_en"]=> string(52) "Bio-Rad Shares Drop After Company Reports 3Q Results" ["snippet_en"]=> string(160) "By Stephen Nakrosis Shares of Bio-Rad Laboratories were trading lower in the after-hours market following the release of third-quarter financial results that..." ["url"]=> string(95) "https://www.marketwatch.com/story/bio-rad-shares-drop-after-company-reports-3q-results-0d9c70ab" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3bebe02f-4333-46c5-bde4-e8e5d9bb24c2" ["source"]=> string(15) "marketwatch.com" ["publication_date"]=> string(10) "2023-10-26" ["categories"]=> array(7) { [0]=> string(15) "Market Movement" [1]=> string(24) "Quarterly/Annual Figures" [2]=> string(21) "Financial Performance" [3]=> string(14) "Issuing Shares" [4]=> string(31) "Financial Update/Profit Warning" [5]=> string(24) "Stock Research & Ratings" [6]=> string(12) "Stock Market" } } [7]=> array(7) { ["title_en"]=> string(84) "Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023" ["snippet_en"]=> string(150) "Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial" ["url"]=> string(140) "https://www.businesswire.com/news/home/20231005466163/en/Bio-Rad-to-Report-Third-Quarter-2023-Financial-Results-on-Thursday-October-26-2023/" ["image_url"]=> NULL ["source"]=> string(16) "businesswire.com" ["publication_date"]=> string(10) "2023-10-05" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" } } [8]=> array(7) { ["title_en"]=> string(46) "Q2 2023 Bio Rad Laboratories Inc Earnings Call" ["snippet_en"]=> string(46) "Q2 2023 Bio Rad Laboratories Inc Earnings Call" ["url"]=> string(74) "https://finance.yahoo.com/news/q2-2023-bio-rad-laboratories-123618854.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/23c247d4-de7a-42c6-a225-c615ba9d7f59" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-08-04" ["categories"]=> array(3) { [0]=> string(5) "Event" [1]=> string(24) "Quarterly/Annual Figures" [2]=> string(31) "Financial Update/Profit Warning" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(66) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(51) } [2]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(31) } [3]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(28) } [4]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(26) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(24) } [6]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(23) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(20) } [8]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(19) } [9]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(19) } [10]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(19) } [11]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(18) } [12]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(14) } [13]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(14) } [14]=> array(2) { ["name"]=> string(18) "Ecological Impacts" ["count"]=> int(13) } [15]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(13) } [16]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(9) } [17]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(9) } [18]=> array(2) { ["name"]=> string(10) "New Market" ["count"]=> int(9) } [19]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(9) } [20]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(8) } [21]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(7) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(7) } [23]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(7) } [24]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(7) } [25]=> array(2) { ["name"]=> string(16) "Case Settlements" ["count"]=> int(6) } [26]=> array(2) { ["name"]=> string(13) "Credit Rating" ["count"]=> int(5) } [27]=> array(2) { ["name"]=> string(15) "Business Ethics" ["count"]=> int(5) } [28]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(5) } [29]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(5) } } } 001cd-us-bio-rad-laboratories-inc